A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER plus advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.

Komal L. Jhaveri, Elgene Lim, Erika P. Hamilton, Cristina Saura, Tarek Meniawy, Rinath Jeselsohn, J. Thaddeus Beck, Peter A. Kaufman, Sarah Sammons, Kalyan Banda, Meena Okera, Kan Yonemori, Kathleen Kiernan Harnden, Sung-Bae Kim, Joohyuk Sohn, Cynthia X. Ma, Philippe Georges Aftimos, Xuejing Aimee Wang, Suzanne R. L. Young, Muralidhar Beeram

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

22 Citations (Web of Science)
Original languageEnglish
Number of pages3
JournalJournal of Clinical Oncology
Issue number15
Publication statusPublished - 20 May 2021

Cite this